Seattle, WA -- (SBWIRE) -- 09/23/2019 -- Pneumococcal vaccine aids in prevention of infection caused by streptococcus pneumoniae bacteria. Pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine are the two types of pneumococcal vaccines. The Centers for Disease Control and Prevention (CDC) recommends pneumococcal conjugate vaccination for all children younger than 2 years old, all adults 65 years or above, and for people 2-64 years old with certain medical conditions. The CDC recommends pneumococcal polysaccharide vaccination for all adults 65 years or above, people 2-64 years old with certain medical conditions, and adults 19-64 years that are addicted to smoking.
The global pneumococcal vaccines market size was valued at US$ 7,376.6 million in 2018 and is expected to witness a CAGR of 7.5% over the forecast period (2018 – 2026).
Request Sample Copy of this Report:https://www.coherentmarketinsights.com/insight/request-sample/2295
Key players in the market are focused on partnering with various governments, which is expected to boost the pneumococcal vaccines market growthPneumonia is associated with high mortality worldwide, which is expected to boost the use of pneumococcal vaccines over the forecast period. For instance, according to the World Health Organization (WHO) November 2016, pneumonia accounted for 16% of all deaths of children under 5 years old in 2015, with 920,136 deaths, globally.
Furthermore, key players in the market are focused on partnering with the Global Alliance for Vaccines and Immunization (GAVI). This is also expected to significantly contribute to the market growth. For instance, in March 2016, GSK (Glaxo Smith Kline) announced the introduction of pneumococcal vaccine at the lowest price - US$ 3.05 from 2017, a reduction of 10% from the 2016 price (US$ 3.40). Such tiered pricing approach enables emerging economies to cater to increasing demand for vaccines for large proportions of the target population. This price is set to be available through the pilot Advance Market Commitment (AMC) to all GAVI countries. Moreover, the vaccine will be sold at the same price for 10 years after transition.
For instance, in April 2016, Glaxo Smith Kline (GSK) and Vodafone collaborated to provide smartphones with an app to various healthcare facilities in northern Mozambique, Africa for a period of one year. The program received funds from GAVI and United States Agency for International Development (USAID) under mVacciNation pilot program. The app enables these healthcare facilities to report regularly on vaccine stock levels and refrigerator temperatures, thereby improving critical supply chain and cold chain management. Furthermore, it helps health workers to register patients, view their vaccination histories, and also allows to send reminders to registered patients for their next vaccination.
Get PDF Brochure of Research Report:https://www.coherentmarketinsights.com/insight/request-pdf/2295
Increasing collaborations among key players to develop and introduce new pneumococcal vaccines and ongoing clinical trial studies on pneumococcal vaccine are expected to drive growth of the pneumococcal vaccines market. For instance, in April 2018, Merck & Co, Inc. initiated two Phase III studies of PCV-15 (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.
Furthermore, in February 2017, Astellas Pharma Inc. and Affinivax, Inc. signed an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae. This partnership would utilize Affinivax's proprietary vaccine technology platform – Multiple Antigen Presenting System (MAPS) to develop a novel vaccine.
Moreover, increasing mortality rate associated with pneumonia, growing awareness regarding pneumonia infection, and its underlying symptoms among the U.S. population are expected to contribute to significant market growth in the region during the forecast period. For instance, according to the American Lung Association: 2015, around 56,832 deaths were registered due to pneumonia and influenza in 2013, which combined were the eighth leading cause of death in the U.S.
Growing healthcare infrastructure in emerging economies such as India and China and increasing initiatives by government bodies to include pneumococcal vaccine in their respective healthcare immunization programs contribute to wider adoption of pneumococcal vaccines in Asia Pacific. For instance, in November 2016, China Food and Drug Administration (CFDA) approved Pfizer, Inc.'s pneumococcal vaccine Prevenar 13, which is indicated to help prevent pneumococcal disease in infants aged between 6 weeks to 15 months.
Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2295
Detailed Segmentation:
By Vaccine Type:
PCV10
PCV13
PPSV23
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Pfizer, Inc.*
Merck & Co. Inc.
GlaxoSmithKline plc
Various manufacturers are focused on new projects that target diseases with no existing vaccine for various age groups. For instance, in April 2018, Merck, which is also known as MSD outside of the U.S. and Canada, started two Phase 3 studies for PCV-15 (V114), an investigational polyvalent conjugate vaccine against pneumococcal disease.
Key players operating in the pneumococcal vaccines market include, Pfizer, Inc., Merck & Co. Inc., and GlaxoSmithKline plc.
To view the original version on The Express Wire visit https://www.coherentmarketinsights.com/market-insight/pneumococcal-vaccines-market-2295
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.